- Home
- RDN vs LQDA Comparison
RDN vs LQDA Comparison
Compare RDN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | LQDA |
|---|---|---|
| Founded | 1977 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.8B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDN | LQDA |
|---|---|---|
| Price | $36.21 | $41.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $43.57 | ★ $54.38 |
| AVG Volume (30 Days) | 1.7M | ★ 4.7M |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 5.61 | ★ 51.81 |
| EPS | ★ 1.74 | 1.26 |
| Revenue | ★ $1,197,084,000.00 | $158,320,000.00 |
| Revenue This Year | $92.73 | $357.27 |
| Revenue Next Year | $7.66 | $1.34 |
| P/E Ratio | ★ $20.38 | $35.87 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $30.53 | $22.31 |
| 52 Week High | $41.05 | $93.61 |
Technical Indicators
Market Signals| Indicator | RDN | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 46.89 |
| Support Level | $35.89 | $35.00 |
| Resistance Level | $37.23 | $46.67 |
| Average True Range (ATR) | 0.81 | 3.03 |
| MACD | 0.24 | 2.27 |
| Stochastic Oscillator | 82.83 | 68.63 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.